JP2023524600A5 - - Google Patents

Info

Publication number
JP2023524600A5
JP2023524600A5 JP2022567867A JP2022567867A JP2023524600A5 JP 2023524600 A5 JP2023524600 A5 JP 2023524600A5 JP 2022567867 A JP2022567867 A JP 2022567867A JP 2022567867 A JP2022567867 A JP 2022567867A JP 2023524600 A5 JP2023524600 A5 JP 2023524600A5
Authority
JP
Japan
Prior art keywords
disease
independently
case
alkyl
structural part
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567867A
Other languages
English (en)
Japanese (ja)
Other versions
JP7874551B2 (ja
JP2023524600A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031297 external-priority patent/WO2021226458A1/en
Publication of JP2023524600A publication Critical patent/JP2023524600A/ja
Publication of JP2023524600A5 publication Critical patent/JP2023524600A5/ja
Priority to JP2026013992A priority Critical patent/JP2026090326A/ja
Application granted granted Critical
Publication of JP7874551B2 publication Critical patent/JP7874551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567867A 2020-05-08 2021-05-07 Akt3モジュレーター Active JP7874551B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026013992A JP2026090326A (ja) 2020-05-08 2026-01-30 Akt3モジュレーター

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063021981P 2020-05-08 2020-05-08
US63/021,981 2020-05-08
US202063121000P 2020-12-03 2020-12-03
US63/121,000 2020-12-03
PCT/US2021/031297 WO2021226458A1 (en) 2020-05-08 2021-05-07 Akt3 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026013992A Division JP2026090326A (ja) 2020-05-08 2026-01-30 Akt3モジュレーター

Publications (3)

Publication Number Publication Date
JP2023524600A JP2023524600A (ja) 2023-06-12
JP2023524600A5 true JP2023524600A5 (cg-RX-API-DMAC10.html) 2024-04-23
JP7874551B2 JP7874551B2 (ja) 2026-06-16

Family

ID=78468458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567867A Active JP7874551B2 (ja) 2020-05-08 2021-05-07 Akt3モジュレーター
JP2026013992A Pending JP2026090326A (ja) 2020-05-08 2026-01-30 Akt3モジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026013992A Pending JP2026090326A (ja) 2020-05-08 2026-01-30 Akt3モジュレーター

Country Status (12)

Country Link
US (1) US20230219927A1 (cg-RX-API-DMAC10.html)
EP (1) EP4146212A4 (cg-RX-API-DMAC10.html)
JP (2) JP7874551B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230022457A (cg-RX-API-DMAC10.html)
CN (1) CN115996721A (cg-RX-API-DMAC10.html)
AU (1) AU2021267930A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022022551A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182012A1 (cg-RX-API-DMAC10.html)
IL (1) IL297600A (cg-RX-API-DMAC10.html)
MX (1) MX2022014021A (cg-RX-API-DMAC10.html)
PH (1) PH12022553016A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021226458A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia
WO2023064493A1 (en) * 2021-10-13 2023-04-20 Clear Creek Bio, Inc. Compounds and methods for treating coronaviruses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158266C (zh) * 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 化合物
US7067532B2 (en) * 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
MX2009006543A (es) * 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
WO2008140895A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
EP2398797B1 (en) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
KR101106050B1 (ko) * 2009-03-25 2012-01-18 한국과학기술연구원 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물
KR101271223B1 (ko) * 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
US10342868B2 (en) 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
KR102537985B1 (ko) * 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
EP3678666B1 (en) 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof

Similar Documents

Publication Publication Date Title
JP2023525757A5 (cg-RX-API-DMAC10.html)
AU2023201399B2 (en) Modulators of the integrated stress pathway
AU2018360855B2 (en) Modulators of the integrated stress pathway
AU2018358157B2 (en) Modulators of the integrated stress pathway
JP7307057B2 (ja) 統合的ストレス経路の調節剤
JP2023524596A5 (cg-RX-API-DMAC10.html)
US20230144871A1 (en) Modulators of the integrated stress pathway
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
JP2021523112A5 (cg-RX-API-DMAC10.html)
HUP0301213A2 (hu) Ciklin dependens kinázok amino-tiazol inhibitorai, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
CA2643177A1 (en) Multi-cyclic compounds for treating cancer
PH12021552760A1 (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
CZ297907B6 (cs) Aminothiazolové deriváty a farmaceutické kompozice s jejich obsahem
RU2011108024A (ru) 3-азабицикло(3.1.0) гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
JP2010528021A5 (cg-RX-API-DMAC10.html)
JP2024541995A5 (cg-RX-API-DMAC10.html)
JP2017532360A5 (cg-RX-API-DMAC10.html)
JP2024540107A5 (cg-RX-API-DMAC10.html)
KR20090055562A (ko) 오로라 a 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
JP2022511477A5 (cg-RX-API-DMAC10.html)
JP2023525756A5 (cg-RX-API-DMAC10.html)
TWI544920B (zh) N-羥基-4-{2-[3-(n,n-二甲基胺基甲基)苯並呋喃-2-基羰基胺基]乙氧基}苯甲醯胺之新穎投藥法
JP2023554391A5 (cg-RX-API-DMAC10.html)
Duran et al. Synthesis of 2-[4, 5-dimethyl-1-(phenylamino)-1 H-imidazol-2-ylthio]-N-(thiazole-2-yl) acetamide derivatives and their anticancer activities
JP2024541994A5 (cg-RX-API-DMAC10.html)